IMVARIA Presents Real-World Clinical Data on FDA-Authorized AI Diagnostic Tool for ILD and IPF at ATS 2025

IMVARIA Inc., a leading health tech company based in Berkeley, California, is set to report multi-site clinical experiences with its FDA-authorized AI diagnostic service, Fibresolve, at the ATS 2025 International Conference in San Francisco. The conference, focused on respiratory diseases, will take place from May 16 to 21, 2025. Fibresolve is the first AI-powered adjunctive diagnostic tool specifically designed to support the assessment of suspected Interstitial Lung Disease (ILD) and Idiopathic Pulmonary Fibrosis (IPF) without disrupting existing clinical workflows. Founded in 2019 by Joshua Reicher, MD, and Michael Muelly, MD, both physician-engineers from Google and Stanford University, IMVARIA has developed Fibresolve to bridge the gap between advanced AI capabilities and practical clinical applications. Unlike many AI tools that require significant integration efforts, Fibresolve can be seamlessly incorporated into a pulmonologist's existing processes. The company emphasizes user-friendly design and compliance with the highest medical standards. Fibresolve received FDA authorization in early 2024 and has since been widely used across the United States. The tool is notable for being the first FDA Breakthrough-Designated AI diagnostic solution with concurrent CPT billing codes by the American Medical Association (AMA), making it both innovative and accessible within the healthcare system. This unique combination of FDA and AMA approvals ensures that the technology is not only trusted but also financially viable for healthcare providers. At the ATS 2025 conference, pulmonary experts from Harvard’s Mass General Hospital will present real-world clinical data on the use of Fibresolve. The poster session, titled "Clinical Experience with the First FDA-Authorized Artificial Intelligence Tool in Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis," will be held on Sunday, May 18, from 9:15 AM to 4:15 PM. The presentation will highlight how Fibresolve has improved diagnostic accuracy and patient outcomes by providing non-invasive, AI-supported evaluations. In addition to Fibresolve, IMVARIA will showcase two other AI solutions: ScreenDx and Bronchosolve. ScreenDx, FDA-cleared in 2025, is designed to detect interstitial lung findings compatible with ILD using computed tomography (CT) scans. A subanalysis from the COPDGene trial will be presented during the same session as Fibresolve, demonstrating the tool's effectiveness in accurately detecting ILD cases. Bronchosolve, an investigational tool, aims to enhance the assessment of indeterminate lung nodules. The poster, "Closed Loop, Full Automation of Suspicious Lung Nodule Risk Assessment with AI in Screening Cases," will be presented on Monday, May 19, from 2:15 PM to 4:15 PM. Another poster, "Age-Stratified Subanalysis of a Closed Loop, Fully Automated Lung Nodule Risk Assessment AI Software," will be presented earlier the same day from 9:15 AM to 4:15 PM. Both sessions will explore how Bronchosolve supports more precise risk stratification and potentially earlier detection of lung cancer. These presentations underscore IMVARIA’s commitment to leveraging AI to improve early and accurate clinical diagnostics. By providing detailed analyses and real-world data, IMVARIA aims to demonstrate the reliability and utility of its AI-driven solutions in pulmonary care. Industry insiders have praised IMVARIA's innovative approach to AI integration in healthcare. The company's ability to create user-friendly, clinically vetted tools has been recognized as a significant step toward making AI more accessible and beneficial for both clinicians and patients. The seamless integration of Fibresolve into existing workflows has particularly impressed medical professionals, who note that it reduces the burden of adopting new technologies. Founded with the vision of transforming clinical decision-making into data science, IMVARIA continues to develop cutting-edge solutions that promise to revolutionize the field of pulmonary medicine. The company's AI lab, equipped with advanced machine-learning algorithms, is dedicated to creating tools that not only deliver reliable insights but also enhance the overall quality of care. With a strong focus on user experience and regulatory compliance, IMVARIA is poised to lead the way in the integration of AI into routine medical practice.